alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM PIMCO
ADVISORS HOLDINGS L.P. FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                          15,620
<SECURITIES>                                         0
<RECEIVABLES>                                   27,801
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                43,421
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 444,148
<CURRENT-LIABILITIES>                           43,651
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       400,497<F1>
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   444,148
<SALES>                                              0<F2>
<TOTAL-REVENUES>                                20,038
<CGS>                                                0<F2>
<TOTAL-COSTS>                                        0<F2>
<OTHER-EXPENSES>                                 3,513
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 16,525
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                             16,525
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    16,525
<EPS-PRIMARY>                                     0.36
<EPS-DILUTED>                                     0.34
<FN>
<F1>Entity is a partnership. Amount shown represents Partners' Capital.
<F2>The partnership is in the service business and has no sales or cost of good
sold on tangible products.
</FN>
        

</TABLE>
§ 74.2331 D&C Red No. 31. ( a ) *Identity and specifications.* The color additive D&C Red No. 31 shall conform in identity and specifications to the requirements of § 74.1331(a)(1) and (b).
( b ) *Uses and restrictions.* D&C Red No. 31 may be safely used for coloring externally applied cosmetics in amounts consistent with good manufacturing practice.
( c ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of D&C Red No. 31 shall be certified in accordance with regulations in part 80 of this chapter.
§ 582.1129 Aluminum potassium sulfate. ( a ) *Product.* Aluminum potassium sulfate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Order entered November 14, 2013

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-12-00151-CR

No. 05-12-00152-CR

JAMES RANDOLPH BELL, Appellant

V.

THE STATE OF TEXAS, Appellee

On Appeal from the Criminal District Court No. 1

Dallas County, Texas

Trial Court Cause Nos. F11-70232-H, F11-70233-H

ORDER

Before the Court are appellant’s Objection to Supplemental Clerk’s Record filed on June 

19, 2013, and Objection to Second Supplemental Clerk’s Record filed on October 28, 2013. We 

OVERRULE the objections.

/s/ JIM MOSELEY 

JUSTICE
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3830 *Treponema pallidum* treponemal test reagents. ( a ) *Identification. Treponema pallidum* treponemal test reagents are devices that consist of the antigens, antisera and all control reagents (standardized reagents with which test results are compared) which are derived from treponemal sources and that are used in the fluorescent treponemal antibody absorption test (FTA-ABS), the *Treponema pallidum* immobilization test (T.P.I.), and other treponemal tests used to identify antibodies to *Treponema pallidum* directly from infecting treponemal organisms in serum. The identification aids in the diagnosis of syphilis caused by bacteria belonging to the genus *Treponema* and provides epidemiological information on syphilis.
( b ) *Classification.* Class II (performance standards).
#### Brotherhood Homes, Inc. *v.*American Surety Company of New York et al.

*William J. Rutler,*for the appellees (defendants).

*F. Timothy McNamara,*for the appellant (plaintiff).

Argued May 6

decided May 6, 1969

The motion by the defendants to dismiss the appeal from the Superior Court in Hartford County is denied.
# C_2015221EN.01001801.xml

| 6.7.2015 | EN | Official Journal of the European Union | C 221/18 |
| --- | --- | --- | --- |

6.7.2015

EN

Official Journal of the European Union

C 221/18

---

Order of the General Court of 16 April 2015 — Yoworld v OHIM — Nestlé (yogorino)

(Case T-246/14) (1)

1

((Community trade mark - Opposition proceedings - Withdrawal of the opposition - No need to adjudicate))

(2015/C 221/24)

Language of the case: English

Parties

Parties

Applicant: Yoworld SA (Luxembourg, Luxembourg) (represented by: A. Tornato and D. Hazan, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: S. Bonne, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM: Société des produits Nestlé SA (Vevey, Switzerland)

Other party to the proceedings before the Board of Appeal of OHIM:

Re:

Re:

Action brought against the decision of the Second Board of Appeal of OHIM of 20 December 2013 (Case R 115/2013-2) concerning opposition proceedings between Société des produits Nestlé SA and Yoworld SA.

Operative part of the order

Operative part of the order

| 1. | There is no longer any need to adjudicate in the action. |
| --- | --- |

1.

There is no longer any need to adjudicate in the action.

| 2. | The applicant and the other party to the proceedings before the Board of Appeal shall bear their own costs and shall each pay half of the costs incurred by the defendant. |
| --- | --- |

2.

The applicant and the other party to the proceedings before the Board of Appeal shall bear their own costs and shall each pay half of the costs incurred by the defendant.

---

(1)  OJ C 235, 21.7.2014.

1

---
A . 

### ''''^>^RT]€NTO F SERVE D JANUAR Y 21 , 201 1

• ^ ,

iI U.S . DEPARTMEN T O FTRANSPORTATIO N OFFIC EO FHEARING S WASHINGTON , D C I NTH EMATTE RO F 

### SAMUE LJOSEP H LATHA M FA A DOCKE T No . CP10WP000 9 (Civi l Penalty Case ) DMS No . FAA-2010-062

4 ORDE RDENYIN GRESPONDENT' S MOTIO NFO RPROTECTIV EORDE R Samue l Josep hLatha m("Respondent " o r "Mr . Latham" ) filed amotio no n Decembe r

6 , 201 0 for

aprotectiv e orde r

unde r sectio n13.22 0 o f

th e Rule s o f

Practic e i n FA A Civi l Penalty Action s ("Rule s o f Practice" ) 1 4 C.F.R . §13.220 . Complainan t Federa l Aviatio n Administratio n ("Complainant" ) ha s answere di nopposition . T o prevai l o n hi s motion , sectio n13.220(h ) o f th e Rule s o f

Practic e require s Mr . Latha mt o sho w tha t

aprotectiv e orde r

i s necessary t o protec t

hi m"fi-o mannoyance , embarrassment , oppression , o r undu e burde no r

expense. " H e ha s not

mad e thi s showing . Th e motio n i s unsupported ; i t contain s n o mor e tha nabar e assertion . Unde r thes e circumstances , th e motio n i s DENIED . Mr . Lathamshal l fulfill th e term s o f th e Orde r

Grantin g Complainant' s Motio n serve dNovembe r

10 , 201 0 ("th e Order" ) b y January 28 , 201 0 (mailin g date) , o r ris k sanction s a s detaile di n Paragrap h3 o f th e Order .1 - . ...:,»:• ; llffl' W ^^g|| M

S O ORDERE D



### Attachmen

t - Servic e Lis t tiv e La w Judg e

^'-3^l.Pi

? *»- j

"i'/' i

k4;£':,-Aikji4^.?it^--.>. vFA A Docke t No . CP10WP000 9 (Civi l Penalty Action ) SERVIC ELIS T ORIGINA L& ON ECOP Y Federal Aviatio n Administratio n 80 0 Independenc e Avenue , S.W . Washington , D C 2059 1 Attention : Hearin g Docke t Clerk , AGC-43 0 Wilbu r Wrigh t Buildin g - Suit e 2W1000 '

ON ECOP Y Samue l Josep hLatham , Responden t 3369 0 Almon dSt . Wildomar , C A 9259 5 TEL : 951-392-489 7 Lierr e Green , Complainant' s Counse l Offic e o f th e Regiona l Counse l Western-Pacifi c Region , AWP- 7 Federal Aviatio n Administratio n P.O . Bo x 9200 7 Lo s Angeles , C A 90009-200 7 TEL : 310-725-711 7 FAX : 310-725-681 6 Th e Honorabl e Richar dC . Goodwin , Administrativ e Law Judg e Offic e o f Hearings , M-2 0 U.S . Departmen t

o f Transportatio n 1200 Ne w Jerse y Avenue , S.E . Eas t Buildin g Groun dFloor , Roo mE12- 3 2 0 Washington , D C 2059 0 TEL : Attorney-Adviso r 202-366-213 9 Legal Assistan t

202-366-512 1 FAX : 202-366-753 6

' Servic e wa s b y U.S . Mail . Fo

r servic e i nperso no r b y expedite dcourier , us e th e followin g address : Hearin g Docket , Federa l Aviatio n Administration, 60

0 Independenc

e Avenue, S.W. , Wilbu

r Wrigh t Buildin g - Roo m 2014, Washington

, D C 20591 , Attention : Hearin

g Docke t Clerk , AGC-430.
# C_2015381EN.01005904.xml

| 16.11.2015 | EN | Official Journal of the European Union | C 381/59 |
| --- | --- | --- | --- |

16.11.2015

EN

Official Journal of the European Union

C 381/59

---

Order of the General Court of 15 September 2015 — Cham and Bena Properties v Council

(Case T-597/14) (1)

1

(2015/C 381/78)

Language of the case: French

The President of the Seventh Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 372, 20.10.2014.

1

---
---

EXHIBIT
32.2





Certification


Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002


(Subsections
(a) and (b) of Section 1350, Chapter 63 of Title 18, United States
Code)





In
connection with the Quarterly Report on Form 10-Q of Southwall Technologies Inc.
(the “Company”), for the period ended March 31, 2009, as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), I, Ms.
Mallorie Burak, the Principal Financial Officer of the Company, do hereby
certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections
(a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
that:





(1)
  The Report of the Company fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2)
  The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the
Company.





Date: November 24,
      2009
            By:
            /s/  Mallorie
      BurakMallorie
      Burak
              Chief
      Accounting Officer





A signed
original of this written statement required by Section 906 has been provided to
the Company and will be retained by the Company and furnished to the Securities
and Exchange Commission or its staff upon request.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1650 Pyruvate kinase test system. ( a ) *Identification.* A pyruvate kinase test system is a device intended to measure the activity of the enzyme pyruvate kinase in erythrocytes (red blood cells). Measurements obtained by this device are used in the diagnosis and treatment of various inherited anemias due to pyruvate kinase deficiency or of acute leukemias.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2308, Jan. 14, 2000]
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.9300 Automated Coombs test systems. ( a ) *Identification.* An automated Coombs test system is a device used to detect and identify antibodies in patient sera or antibodies bound to red cells. The Coombs test is used for the diagnosis of hemolytic disease of the newborn, and autoimmune hemolytic anemia. The test is also used in crossmatching and in investigating transfusion reactions and drug-induced red cell sensitization.
( b ) *Classification.* Class II (performance standards).
[45 FR 60646, Sept. 12, 1980]
§ 814.15 Research conducted outside the United States. ( a ) *Data to support PMA.* If data from clinical investigations conducted outside the United States are submitted to support a PMA, the applicant shall comply with the provisions in § 812.28 of this chapter, as applicable.
( b ) *As sole basis for marketing approval.* A PMA based solely on foreign clinical data and otherwise meeting the criteria for approval under this part may be approved if: ( 1 ) The foreign data are applicable to the U.S. population and U.S. medical practice;
( 2 ) The studies have been performed by clinical investigators of recognized competence; and
( 3 ) The data may be considered valid without the need for an on-site inspection by FDA or, if FDA considers such an inspection to be necessary, FDA can validate the data through an on-site inspection or other appropriate means.
( c ) *Consultation between FDA and applicants.* Applicants are encouraged to meet with FDA officials in a “presubmission” meeting when approval based solely on foreign data will be sought.
[51 FR 26364, July 22, 1986; 51 FR 40415, Nov. 7, 1986, as amended at 51 FR 43344, Dec. 2, 1986; 83 FR 7387, Feb. 21, 2018]
**Exhibit23.1**

 

**CONSENT OF KPMG LLP, INDEPENDENT AUDITORS**

 

 

The Board of Directors

Mackie Designs Inc.:

 

We consent to the incorporation by reference in theregistration statement (No. 33-98720) on Form S-8 of Mackie Designs Inc. of ourreport dated February 28, 2002, except as to Note 8 which is as of April 18,2002, relating to the consolidated balance sheets of Mackie Designs Inc. as ofDecember 31, 2001 and 2000 and the related consolidated statements ofoperations, cash flows and shareholders’ equity and comprehensive income (loss)for each of the years in the three-year period ended December 31, 2001 whichreport appears in the December 31, 2001 annual report on Form 10-K ofMackie Designs Inc.

 

 

/s/ KPMG LLP

 

Seattle, Washington

April 22, 2002
<TABLE> <S> <C>

<ARTICLE> 9
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE FOURTH
QUARTER/ FISCAL YEAR END 10-K AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH 10-K.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                                     <C>
<PERIOD-TYPE>                           YEAR
<FISCAL-YEAR-END>                       SEP-30-1996
<PERIOD-END>                            SEP-30-1996
<CASH>                                        6,842
<INT-BEARING-DEPOSITS>                            0
<FED-FUNDS-SOLD>                              9,338
<TRADING-ASSETS>                                  0
<INVESTMENTS-HELD-FOR-SALE>                 150,096
<INVESTMENTS-CARRYING>                       16,610
<INVESTMENTS-MARKET>                         16,596
<LOANS>                                     473,556
<ALLOWANCE>                                     928
<TOTAL-ASSETS>                              671,969
<DEPOSITS>                                  399,673
<SHORT-TERM>                                 79,904
<LIABILITIES-OTHER>                          13,981
<LONG-TERM>                                  25,000
<PREFERRED-MANDATORY>                             0
<PREFERRED>                                       0
<COMMON>                                        116
<OTHER-SE>                                  153,295
<TOTAL-LIABILITIES-AND-EQUITY>              671,969
<INTEREST-LOAN>                              35,262
<INTEREST-INVEST>                             8,867
<INTEREST-OTHER>                              1,520
<INTEREST-TOTAL>                             45,649
<INTEREST-DEPOSIT>                           20,251
<INTEREST-EXPENSE>                           23,287
<INTEREST-INCOME-NET>                        22,363
<LOAN-LOSSES>                                   120
<SECURITIES-GAINS>                           (1,643)
<EXPENSE-OTHER>                              10,600
<INCOME-PRETAX>                              10,522
<INCOME-PRE-EXTRAORDINARY>                   10,522
<EXTRAORDINARY>                                   0
<CHANGES>                                         0
<NET-INCOME>                                  6,110
<EPS-PRIMARY>                                   .56
<EPS-DILUTED>                                   .56
<YIELD-ACTUAL>                                 2.22
<LOANS-NON>                                     191
<LOANS-PAST>                                      0
<LOANS-TROUBLED>                                 79
<LOANS-PROBLEM>                                   0
<ALLOWANCE-OPEN>                                808
<CHARGE-OFFS>                                     0
<RECOVERIES>                                      0
<ALLOWANCE-CLOSE>                               928
<ALLOWANCE-DOMESTIC>                              0
<ALLOWANCE-FOREIGN>                               0
<ALLOWANCE-UNALLOCATED>                         928

        

</TABLE>
# United States Court of Appeals

f or the Fifth Circuit

No. 22

- 60190 Summary Calendar

Corla Jackson,

Plaintiff

— Appellant ,

versus

Siegel Group, L.L.C.; Jason Weber; Siegel Group Nevada, Incorporated; Stephen Siegel, also known as Steve Siegel; Imagination Holdings,L.L.C.; 3491 Dolphin Gautier Holdings, L.L.C.; Siegel Group,

Defendants

— Appellees

.

Appeal from the United States Di strict Court for the Southern District of Mississippi USDC No. 1:20

- CV

- 355

Before Jones, Stewart, and Haynes , Circuit Judges

. Per Curiam : *
Plaintiff Corla Jackson appeals the district court’s dismissal of her
claims and its decision to set aside the entry of default against several

* Pursuant to 5th Cir cuit R ule 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5th Cir cuit R ule 47.5.4. United States Court of Appeals Fifth Circuit 

### FILED December 21, 2022
Lyle W. Cayce Clerk Case: 22-60190 Document: 00516585988 Page: 1 Date Filed: 12/21/2022No. 22

- 60190

2 defendants . All Jackson’s claims stem from what she characterizes as her wrongful eviction from her apartment. The defendants are various legal

persons that Jackson claims constitute her former landlord (collectively the “Sieg e l defendants”) as well as Jason Weber, the general manager of the

property.
Jackson obtained entries of default against the Sieg e l defendan ts for their failure to respond . The Sieg e l defendants then appeared, arguing that they had been improperly served and that good cause existed to set aside the default. They also sought dismissal of all claims on the ground that Jackson
had not been evic ted.

The district court set aside the default and dismissed all of Jackson’s
claims. He found good cause to set aside the default for several reasons, including that the recipient of the summons

— a receptionist at one of the
defendants’ corporate headquarters

— was not an agent authorized to receive service for any of the Siegel defendants. He also dismissed all federal claims with prejudice. He found no factual allegations to support her claims under

42 U.S.C. § 19 82 or the Fair Housing Act. And he found her claim based on the CDC’s eviction moratorium mooted by the Supreme Court’s decision in Alabama Ass’n of Realtors v. Dep’t of Health & Hum. Servs. , 141 S. Ct. 2485 (2021). The Fifth and Fourteenth Amendment cla ims were dismissed for the
lack of state action. Finally, he dismissed all state claims without prejudice. He found that the court lacked diversity jurisdiction because W e ber was a citizen of the same state as Jackson , a nd he declined to exercise suppleme ntal jurisdiction over the state law claims after considering the factors laid out in

28 U.S.C. § 1367(c)

. The judgment of the district court is AFFIRMED. We find no reversible error of law or fact and affirm essentially for the reasons stated in
the thor ough opinion of the district court. Case: 22-60190 Document: 00516585988 Page: 2 Date Filed: 12/21/2022
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1275 Estrogens (total, nonpregnancy) test system. ( a ) *Identification.* As estrogens (total, nonpregnancy) test system is a device intended to measure the level of estrogens (total estrone, estradiol, and estriol) in plasma, serum, and urine of males and nonpregnant females. Measurement of estrogens (total, nonpregnancy) is used in the diagnosis and treatment of numerous disorders, including infertility, amenorrhea (absence of menses) differentiation of primary and secondary ovarian malfunction, estrogen secreting testicular and ovarian tumors, and precocious puberty in females.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2306, Jan. 14, 2000]
Exhibit 99(b)


        Written Statement of the Vice President Law/Finance and Secretary
                          Pursuant to 18 U.S.C. ss. 1350

         Solely for the purposes of complying with 18 U.S.C. ss. 1350, I, the
undersigned Vice President Law/Finance and Secretary of Ladish Co., Inc. (the
"Company"), hereby certify, based on my knowledge, that the Quarterly Report on
Form 10-Q of the Company for the quarter ended September 30, 2002 (the "Report")
fully complies with the requirements of Section 13(a) of the Securities Exchange
Act of 1934, and that information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the
Company.




 /s/  Wayne E. Larsen
-------------------------------
Wayne E. Larsen
November 11, 2002
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1255 Balloon aortic valvuloplasty catheter. ( a ) *Identification.* A balloon aortic valvuloplasty catheter is a catheter with a balloon at the distal end of the shaft, which is intended to treat stenosis in the aortic valve when the balloon is expanded.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) The device must be demonstrated to be biocompatible.
( 2 ) Sterility and shelf life testing must demonstrate the sterility of patient-contacting components and the shelf life of these components.
( 3 ) Non-clinical performance evaluation must demonstrate that the device performs as intended under anticipated conditions of use, including device delivery, inflation, deflation, and removal.
( 4 ) In vivo evaluation of the device must demonstrate device performance, including the ability of the device to treat aortic stenosis.
( 5 ) Labeling must include a detailed summary of the device-related and procedure-related complications pertinent to the use of the device.
[82 FR 34852, July 27, 2017]